Abstract
Background Senaparib, a novel poly(ADP-ribose) polymerase 1/2 inhibitor, demonstrated antitumor activity in preclinical studies. This phase I, first-i......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
